BCRX.O PE Ratio & Valuation, Is BCRX.O Overvalued

Historical Valuation

BioCryst Pharmaceuticals Inc (BCRX.O) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.27 is considered Undervalued compared with the five-year average of -26.05. The fair price of BioCryst Pharmaceuticals Inc (BCRX.O) is between 45.39 to 67.24 according to relative valuation method. Compared to the current price of 9.41 USD , BioCryst Pharmaceuticals Inc By Undervalued By 79.27%.

Relative Value

Fair Zone

45.39-67.24

Current Price：9.41

79.27%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is BioCryst Pharmaceuticals Inc (BCRX.O) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

BioCryst Pharmaceuticals Inc (BCRX.O) has a current Price-to-Book (P/B) ratio of -20.12. Compared to its 3-year average P/B ratio of -4.65, the current P/B ratio is approximately 332.82% higher. Relative to its 5-year average P/B ratio of -9.77, the current P/B ratio is about 105.91% higher. BioCryst Pharmaceuticals Inc (BCRX.O) has a Forward Free Cash Flow (FCF) yield of approximately 13.70%. Compared to its 3-year average FCF yield of -2.94%, the current FCF yield is approximately -566.13% lower. Relative to its 5-year average FCF yield of -4.64%, the current FCF yield is about -395.53% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BCRX competitors is 62.51, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX.O) exhibits a P/S ratio of --, which is NaN% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BCRX.O increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BCRX.O in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BCRX.O currently overvalued or undervalued?

BioCryst Pharmaceuticals Inc (BCRX.O) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.27 is considered Undervalued compared with the five-year average of -26.05. The fair price of BioCryst Pharmaceuticals Inc (BCRX.O) is between 45.39 to 67.24 according to relative valuation method. Compared to the current price of 9.41 USD, BioCryst Pharmaceuticals Inc is Undervalued By 79.27%.

What is BioCryst Pharmaceuticals Inc (BCRX.O) fair value?

BCRX.O's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BioCryst Pharmaceuticals Inc (BCRX.O) is between 45.39 to 67.24 according to relative valuation method.

How does BCRX.O's valuation metrics compare to the industry average?

The average P/S ratio for BCRX.O's competitors is 62.51, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX.O) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for BioCryst Pharmaceuticals Inc (BCRX.O) as of Apr 14 2026?

As of Apr 14 2026, BioCryst Pharmaceuticals Inc (BCRX.O) has a P/B ratio of -20.12. This indicates that the market values BCRX.O at -20.12 times its book value.

What is the current FCF Yield for BioCryst Pharmaceuticals Inc (BCRX.O) as of Apr 14 2026?

As of Apr 14 2026, BioCryst Pharmaceuticals Inc (BCRX.O) has a FCF Yield of 13.70%. This means that for every dollar of BioCryst Pharmaceuticals Inc's market capitalization, the company generates 13.70 cents in free cash flow.

What is the current Forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX.O) as of Apr 14 2026?

As of Apr 14 2026, BioCryst Pharmaceuticals Inc (BCRX.O) has a Forward P/E ratio of 119.05. This means the market is willing to pay $119.05 for every dollar of BioCryst Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BioCryst Pharmaceuticals Inc (BCRX.O) as of Apr 14 2026?

As of Apr 14 2026, BioCryst Pharmaceuticals Inc (BCRX.O) has a Forward P/S ratio of 3.27. This means the market is valuing BCRX.O at $3.27 for every dollar of expected revenue over the next 12 months.

BCRX.O Valuation